Invesco Pharmaceuticals vs iShares Healthcare: Which Healthcare ETF Brings Better Profits

Invesco Pharmaceuticals ETF (PJP) returned 43.1% over the past year versus 27.4% for iShares U.S. Healthcare ETF (IYH), and also led year-to-date (16.4% vs. 14.5%) and over three- and five-year annualized periods. PJP offers concentrated exposure to 27 pharmaceutical stocks and carries a 0.57% expense ratio, compared with IYH's broader 100-stock healthcare portfolio and lower 0.37% fee. Despite its higher small-cap allocation, PJP posted a slightly smaller five-year maximum drawdown of 17.5% versus 17.9%, leading the article to favor PJP, while IYH retains stronger 10-year annualized performance of 10.5% versus 8.1%.

Analysis

The relevant distinction is not diversification but factor exposure: PJP is effectively a tilted expression of U.S. pharma/smaller-cap drug-development risk, while IYH embeds a substantially larger single-stock exposure to LLY and therefore to GLP-1 growth-duration and valuation risk. A broad healthcare allocation through IYH may behave less defensively than investors expect if LLY de-rates; PJP should be relatively more insulated from an idiosyncratic obesity-drug multiple reset, though it remains exposed to drug-pricing policy and patent-cycle risk.

PJP's recent relative strength should not be extrapolated mechanically. Its smaller-cap allocation introduces greater sensitivity to financing conditions, M&A expectations, and clinical/regulatory outcomes; if rates fall or pharma dealmaking accelerates over the next 3-12 months, that optionality can sustain the premium. Conversely, a risk-off move, FDA safety surprise, or renewed Washington focus on Medicare drug-price negotiation would likely hurt PJP more than IYH despite backward-looking drawdown statistics.

The non-obvious competitive implication is that an obesity-drug supply normalization could redistribute healthcare returns: LLY's scarcity premium could compress while payer, distributor, medtech and diagnostics utilization beneficiaries gain. IYH does not provide a clean hedge against that scenario because its large-cap construction leaves the fund materially dependent on LLY; investors seeking defensive healthcare beta should assess constituent-level concentration rather than assume the broader label reduces risk.

This is routine comparative ETF commentary rather than a fresh earnings or regulatory catalyst, so there is no standalone near-term trade signal. The actionable question is whether the PJP/IYH relative-performance spread is being driven by durable pharma earnings revisions and M&A probability, or simply momentum; monitor forward EPS revisions, LLY's weight and valuation, and 10-year Treasury yields before adding exposure.

Key Decisions for Investors

• Use PJP/IYH as a 3-6 month relative-value watch: initiate long PJP / short IYH only after PJP relative strength is confirmed by improving consensus 2027 EPS revisions for AMGN, MRK and ABBV; target 8-12% relative return, with a 5% adverse relative-move stop.
• For existing IYH holders, cap implicit LLY exposure at portfolio level rather than treating the ETF as diversified healthcare. Hedge or reduce IYH if LLY guidance, prescription-growth data, or gross-margin commentary indicates GLP-1 supply-demand normalization; that is the clearest catalyst for multiple compression over 1-3 months.
• Prefer individual ABBV or MRK exposure over a broad PJP allocation for investors seeking large-cap pharma defensiveness: each offers more identifiable earnings/cash-flow drivers and avoids PJP's smaller-cap clinical and financing beta. Reassess on material Medicare negotiation developments or pipeline setbacks.
• Avoid using the reported historical drawdown differential as a risk-sizing input. Stress PJP against a 75-100 bp rise in real yields and a closed biotech financing window; reduce relative-long exposure if smaller-cap healthcare underperforms XBI materially for two consecutive weeks.